Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the successful completion of the ...
Merck narrowed its 2026 sales guidance and hiked its adjusted profit outlook.
Terns is now a wholly-owned subsidiary of Merck and its stock will no longer be listed or traded on the Nasdaq Global Select ...
Merck (NYSE:MRK | MRK Price Prediction) delivered its fourth consecutive earnings beat, but shares slipped on the earnings ...
Merck faces falling sales for its key drugs including a blockbuster HPV vaccine and diabetes medication.
MSD (Merck) will acquire Terns Pharmaceuticals for approximately USD 6.7 billion, adding investigational leukemia therapy ...
Despite updated study data that suggest Terns’ treatment may be less differentiated, company executives claimed Thursday that ...
Feb 23 (Reuters) - Merck said on Monday it would create a separate division for its cancer business, anchored by its top-selling drug Keytruda, as the U.S. drugmaker braces for the upcoming patent ...
As Merck considers its life after Keytruda, much will depend on the performance of a pair of respiratory products it gained ...
Merck is tapping a number of baseball ambassadors to support its cardiovascular awareness push, including former World Series ...
Merck, known as MSD outside of the United States and Canada, announced the successful completion of the acquisition of Terns Pharmaceuticals, Inc. (Terns). “The Terns acquisition reflects Merck’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results